Phase II NCCTG trial of RT + irinotecan and adjuvant BCNU plus irinotecan for newly diagnosed GBM

Irinotecan has radiosensitizing effects and shows synergism with nitrosoureas. We performed a Phase II study of RT and irinotecan, followed by BCNU plus irinotecan in newly-diagnosed GBM. The MTD for patients receiving enzyme-inducing anticonvulsants (EIAC) was as follows: irinotecan 400 mg/m(2)/wee...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Jaeckle, Kurt A., Ballman, Karla V., Giannini, Caterina, Schomberg, Paula J., Ames, Matthew M., Reid, Joel M., McGovern, Renee M., Safgren, Stephanie L., Galanis, Evanthia, Uhm, Joon H., Brown, Paul D., Hammack, Julie E., Arusell, Robert, Nikcevich, Daniel A., Morton, Roscoe F., Wender, Donald B., Buckner, Jan C.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2010
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC2897141/
https://ncbi.nlm.nih.gov/pubmed/20063115
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11060-009-0103-2
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak